Search
Now showing items 1-5 of 5
Targeted immunotherapy with a checkpoint inhibitor in combination with chemotherapy: A new clinical paradigm in the treatment of triple-negative breast cancer.
(
Association of Basic Medical Sciences of Federation of Bosnia and Herzegovina
, 2019 , Article Review)
The treatment of several solid and hematologic malignancies with immune checkpoint inhibitors (against PD-1/PD-L1) has dramatically changed the cancer treatment paradigm. However, no checkpoint inhibitors were previously ...
Novel targetable biomarkers in clear cell carcinoma of the breast uncovered by molecular profiling: A study of nine cases.
(
Wiley
, 2020 , Article)
We profiled nine pure clear cell carcinomas of the breast using massively parallel DNA and RNA sequencing (NGS), in situ hybridization (ISH), and immunohistochemistry (IHC). All cases were primary mammary clear cell ...
High-Risk HPV Oncoproteins and PD-1/PD-L1 Interplay in Human Cervical Cancer: Recent Evidence and Future Directions
(
Frontiers Media
, 2020 , Article)
Cervical cancer is the fourth most common malignancy in women worldwide and a leading cause of cancer-related mortality in developing countries. Important etiological factors in this cancer are high-risk human papillomaviruses ...
PD-L1 testing by immunohistochemistry in Immuno-Oncology.
(
Association of Basic Medical Sciences of Federation of Bosnia and Herzegovina
, 2022 , Article Review)
Immunotherapy, based on immune checkpoint inhibitors targeting the Programmed cell death ligand 1 (PD-L1) and/or Programmed Death Receptor 1 (PD-1), has substantially improved the outcomes of patients with various cancers. ...
PD-L1 status in breast cancer: Current view and perspectives.
(
Elsevier
, 2019 , Article)
Breast cancer was traditionally not considered a particularly immunogenic tumor. However, recent developments have shown that some aggressive triple-negative breast cancers are immunogenic, exhibit a resistance to chemotherapy ...